A5034419548- Pharmaceutical Economics and Policy
- Eosinophilic Disorders and Syndromes
- Biosimilars and Bioanalytical Methods
- Blood disorders and treatments
- Gout, Hyperuricemia, Uric Acid
- Case Reports on Hematomas
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Health Systems, Economic Evaluations, Quality of Life
IQVIA (United States)
2022-2023
IQ Solutions
2023
Aim: Patients with secondary immunodeficiency (SID) are at increased risk of infections and may be treated immunoglobulin replacement therapy (IgRT). Despite growing efficacy evidence for IgRT in infection prevention SID, treatment guidelines not aligned. Materials & methods: A retrospective database analysis was conducted to assess patterns rates patients SID-related infections, or without (IgPro10) exposure, evaluate real-world effectiveness prevention. Results: Of 11,448 included, 222...
This drug utilization study evaluated the impact of 2019 label changes on real-world febuxostat among patients with gout. We describe numbers and proportions initiating as new users (allopurinol-naïve) or prevalent (prior allopurinol use) data established cardiovascular disease (CVD) morbidities before, during, after changes.This descriptive, non-interventional, cross-sectional used from two large administrative claims databases in United States, IQVIA PharMetrics Plus database Optum...